Trends Immunol. 2025 Apr 22:S1471-4906(25)00078-X. doi: 10.1016/j.it.2025.03.004. Online ahead of print.
ABSTRACT
The development of ionizable mRNA-lipid nanoparticle (mRNA-LNP) nucleic acid carriers facilitated the clinical translation of the Coronavirus 2019 (COVID-19) mRNA vaccines BNT162b2 and mRNA-1273. Here, we discuss insights into rational improvements to mRNA vaccines, focusing on LNP modifications for mRNA-LNP biodistribution control, miRNA-based biodistribution control of encoded transcripts, and precision adjuvantation strategies.
PMID:40268657 | DOI:10.1016/j.it.2025.03.004